The development of new therapeutic monoclonal antibodies (mAbs) for cancer therapy will rise in the following years. The evaluation of biological activity of mAbs is required during drug development and during drug production as quality control test. Antibody-dependent cell-mediated cytotoxicity (ADCC) is a desirable activity of anticancer mAbs. Here, we describe a flow cytometry-based method to quantify ADCC that combines the staining of cancer cells, effector cells, and dead cells, with specific dyes. This method is inexpensive, has low background, and avoids the use of radioisotopes.
ADCC Flow cytometry Trastuzumab 7-AAD Biosimilar
This is a preview of subscription content, log in to check access.
Springer Nature is developing a new tool to find and evaluate Protocols. Learn more
We thank Dr. Frank Robledo-Avila and Dra. Mayra Pérez-Tapia for the critical review of this manuscript. Assays presented in this work were performed at “Unidad de Desarrollo e Investigación en Bioprocesos (UDIBI), Instituto Politécnico Nacional.” The work is supported by a grant from “Instituto Científico Pfizer, México” and grants IN219613 (PAPIIT-UNAM) and 225313 (Conacyt) to MAV-V.
Harrison A, Liu Z, Makweche S et al (2012) Methods to measure the binding of therapeutic monoclonal antibodies to the human Fc receptor FcgammaRIII (CD16) using real time kinetic analysis and flow cytometry. J Pharm Biomed Anal 63:23–28PubMedCrossRefGoogle Scholar
Derby E, Reddy V, Kopp W et al (2001) Three-color flow cytometric assay for the study of the mechanisms of cell-mediated cytotoxicity. Immunol Lett 78:35–39PubMedCrossRefGoogle Scholar
Collins DM, O'Donovan N, McGowan PM et al (2012) Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines. Ann Oncol 23:1788–1795PubMedCrossRefGoogle Scholar
Yeo C, Saunders N, Locca D et al (2009) Ficoll-Paque versus Lymphoprep: a comparative study of two density gradient media for therapeutic bone marrow mononuclear cell preparations. Regen Med 4:689–696PubMedCrossRefGoogle Scholar
Green MR, Kennell AS, Larche MJ et al (2005) Natural killer cell activity in families of patients with systemic lupus erythematosus: demonstration of a killing defect in patients. Clin Exp Immunol 141:165–173PubMedCentralPubMedCrossRefGoogle Scholar